These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6696702)

  • 61. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans.
    Stoops WW; Lile JA; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2005 Feb; 13(1):56-64. PubMed ID: 15727504
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of treatment strategies for Space Motion Sickness.
    Davis JR; Jennings RT; Beck BG
    Acta Astronaut; 1993 Aug; 29(8):587-91. PubMed ID: 11541638
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anti-emetic drug effects on pilot performance: granisetron vs. ondansetron.
    Benline TA; French J; Poole E
    Aviat Space Environ Med; 1997 Nov; 68(11):998-1005. PubMed ID: 9383499
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Human centrifuge studies on the relative effectiveness of some antimotion sickness drugs.
    Wood CD; Graybiel A; McDonough R
    Aerosp Med; 1966 Feb; 37(2):187-90. PubMed ID: 5906041
    [No Abstract]   [Full Text] [Related]  

  • 65. Comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room.
    Wood CD; Graybiel A; Kennedy RS
    Aerosp Med; 1966 Mar; 37(3):259-62. PubMed ID: 5907763
    [No Abstract]   [Full Text] [Related]  

  • 66. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.
    Zhang LL; Liu HQ; Yu XH; Zhang Y; Tian JS; Song XR; Han B; Liu AJ
    CNS Neurosci Ther; 2016 Aug; 22(8):715-22. PubMed ID: 27160425
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers.
    Gandia P; Saivin S; Le-Traon AP; Guell A; Houin G
    J Clin Pharmacol; 2006 Sep; 46(9):1008-16. PubMed ID: 16920895
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Scopolamine blood levels following buccal versus ingested tablets.
    Golding JF; Gosden E; Gerrell J
    Aviat Space Environ Med; 1991 Jun; 62(6):521-6. PubMed ID: 1859338
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness.
    Killgore WD; Rupp TL; Grugle NL; Reichardt RM; Lipizzi EL; Balkin TJ
    J Sleep Res; 2008 Sep; 17(3):309-21. PubMed ID: 18522689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nuclear medicine evaluation of motion sickness and medications on gastric emptying time.
    Wood MJ; Wood CD; Manno JE; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Nov; 58(11):1112-4. PubMed ID: 3318799
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of promethazine to hasten adaptation to provocative motion.
    Lackner JR; Graybiel A
    J Clin Pharmacol; 1994 Jun; 34(6):644-8. PubMed ID: 8083396
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine.
    Boyd JL; Du B; Vaksman Z; Locke JP; Putcha L
    J Gravit Physiol; 2007 Jul; 14(1):P107-8. PubMed ID: 18372722
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of histaminergic drugs in experimental motion sickness.
    Matsnev EI; Sigaleva EE
    J Vestib Res; 2007; 17(5-6):313-21. PubMed ID: 18626141
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Instrument flight performance under the influence of certain combinations of antiemetic drugs.
    Hyman FC; Collins WE; Taylor HL; Domino EF; Nagel RJ
    Aviat Space Environ Med; 1988 Jun; 59(6):533-9. PubMed ID: 3390111
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of transdermal scopolamine upon psychological test performance at sea.
    Parrott AC; Jones R
    Eur J Clin Pharmacol; 1985; 28(4):419-23. PubMed ID: 4029247
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
    Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
    Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Motion sickness and its treatment (author's transl)].
    Petrin A
    Schweiz Rundsch Med Prax; 1974 Jan; 63(3):79-81. PubMed ID: 4153225
    [No Abstract]   [Full Text] [Related]  

  • 80. Evaluation of the effects of anti-motion sickness drugs on subjective sleepiness and cognitive performance of healthy males.
    Weerts AP; Pattyn N; Van de Heyning PH; Wuyts FL
    J Psychopharmacol; 2014 Jul; 28(7):655-64. PubMed ID: 24346808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.